|
WO2009033809A2
|
|
Use of a peptide as a therapeutic agent
|
|
WO2009043524A2
|
|
Use of a peptide as therapeutic agent
|
|
WO2009033818A2
|
|
Use of a peptide as a therapeutic agent
|
|
WO2009040050A2
|
|
Use of calcitonin as anti-angiogenic agent
|
|
WO2009039971A2
|
|
Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
|
|
WO2009033810A2
|
|
Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
|
|
WO2009043463A2
|
|
Use of gluten exorphin c : as a therapeutic agent
|
|
WO2009046880A2
|
|
Use of a peptide as a therapeutic agent
|
|
WO2009033812A2
|
|
Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
|
|
WO2009046877A2
|
|
Use of a histrelin and leuprolide as therapeutic agents
|
|
WO2009046872A2
|
|
Use of a peptide as a therapeutic agent
|
|
WO2009033822A2
|
|
Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent
|
|
WO2009033820A2
|
|
Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
|
|
WO2009033808A2
|
|
Use of a peptide as a therapeutic agent
|
|
WO2006072579A1
|
|
Pharmaceutically active antiviral peptides
|
